Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

Presentation ACC 2024

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Presenter: Steven E. Nissen

April 08, 2024

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Conference News ACC 2021

New STRENGTH Analysis Revives Omega-3 Debate

Todd Neale

May 20, 2021

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Conference News ACC 2014

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

Jason Kahn

March 31, 2014

News Conference News ACC 2013

Will Watchman PREVAIL? Positive Study Pulled from ACC Meeting

Yael L. Maxwell

March 08, 2013

Video

» Interview

APOLLO Trial: Magnitude And Duration of Effects of A Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial

May 4, 2022

Advertisement

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

Need a Statin for Primary Prevention? There’s an App for That

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

New STRENGTH Analysis Revives Omega-3 Debate

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

Will Watchman PREVAIL? Positive Study Pulled from ACC Meeting

APOLLO Trial: Magnitude And Duration of Effects of A Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content